Meanwhile, regarding clinical trials, it was noted that the Nrf2 activator bardoxolone methyl did not reduce the risk of death due to ESRD in patients with type 2 diabetes and stage 4 chronic kidney disease. Here, NFE2L2 is linked to chronic kidney disease.